Clinical Scorecard: Comprehensive Review: Impact of Medical Interventions on Pediatric Outcomes in X-Linked Hypophosphatemia
At a Glance
Category
Detail
Condition
X-linked hypophosphatemia (XLH), a rare genetic disorder causing hypophosphatemia due to elevated FGF23 levels impairing phosphate reabsorption and vitamin D metabolism
Key Mechanisms
PHEX gene mutations lead to elevated FGF23, causing renal phosphate wasting and decreased 1,25(OH)2D synthesis, resulting in hypophosphatemia and impaired bone mineralization
Target Population
Children under 18 years with clinically or genetically confirmed XLH
Care Setting
Pediatric clinical settings managing rare metabolic bone disorders
Key Highlights
Burosumab probably prevents lower limb deformity and improves physical health quality of life compared to conventional therapy (moderate certainty).
Burosumab may increase height and reduce symptom burden related to chronic hypophosphatemia (low certainty).
Burosumab probably increases treatment-emergent adverse events and may increase dental abscesses.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on pathogenic PHEX gene variants or clinical features including family history, biochemical evidence of hypophosphatemia, low TmP/GFR, elevated ALP, or radiographic rickets.
Management
Conventional therapy includes phosphate salts and active vitamin D supplementation.
Burosumab, a monoclonal antibody against FGF23, is recommended to prevent skeletal deformities and improve quality of life in children with XLH.
Monitoring & Follow-up
Monitor for treatment-emergent adverse events, including dental abscesses, especially when using burosumab.
Regular assessment of growth parameters, skeletal deformities, and quality of life.
Risks
Burosumab treatment may increase adverse events and dental abscess risk.
Limited evidence on long-term effects of conventional therapy on final height and other outcomes.
Patient & Prescribing Data
Children under 18 years with confirmed XLH
Burosumab shows moderate certainty evidence for benefits in preventing lower limb deformities and improving physical QoL but may increase adverse events; conventional therapy evidence is limited and of very low certainty regarding final height impact.
Clinical Best Practices
Early diagnosis and initiation of treatment to optimize growth and prevent bone deformities.
Consider burosumab for children with XLH to improve physical health outcomes, balancing benefits against potential adverse events.
Use conventional therapy when burosumab is unavailable or contraindicated, acknowledging limited evidence on long-term outcomes.
Regularly monitor biochemical markers, growth, skeletal deformities, dental health, and quality of life.
Engage multidisciplinary teams for comprehensive management including endocrinology, orthopedics, and dentistry.
by Dalal S Ali, Reza D Mirza, Salma Hussein, Farah Alsarraf, R Todd Alexander, Hajar Abu Alrob, Natasha M Appelman-Dijkstra, Martin Biosse-Duplan, Maria Luisa Brandi, Thomas O Carpenter, Catherine Chaussain, Karel Dandurand, Guido Filler, Pablo Florenzano, Seiji Fukumoto, Corinna Grasemann, Erik A Imel, Suzanne M Jan de Beur, Emmett Morgante, Leanne M Ward, Aliya A Khan, Gordon Guyatt
More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.
